'Miracle' drug Dostarlimab gives astonishing results as cancer vanishes from 12 people

Описание: Can there be a radiation-free treatment for Cancer?
Sascha Roth was diagnosed with rectal cancer and was planning to move cities for treatment, when her friend suggested she meet a surgeon at the Memorial Sloan Kettering Cancer Centre in New York. She became the first patient in a trial where Dostarlimab — a cancer drug developed by British multinational pharmaceutical company GlaxoSmithKline plc — was tested in the early stages of the disease. Roth has been cancer-free for two years now.
According to the study published in the New England Journal of Medicine on June 5, 2022, the trial was conducted on 12 people who were diagnosed with Stage II or Stage III rectal cancer. The traditional treatment for this is radiation, followed by chemotherapy and surgery which could likely result in neuropathy, infertility, bowel, urinary and sexual dysfunction. The patients were administered Dostarlimab every three weeks for six months. All the patients undergoing the trial had no sign of cancer for a year after the treatment. Hence, there was no need for chemotherapy or surgery.
“What’s really remarkable is, this is the first time I know of solid tumour oncology where we’ve had a 100 percent complete response, and we’ve completely omitted the normal standard of care,” Luis Diaz, head of the division of solid tumour oncology at Memorial Sloan Kettering,
But that is not all. No adverse events of Grade 3 or higher were reported, the study found. Grade 3 or higher typically means significant symptoms requiring hospitalization or invasive intervention.
Dr. Hanna K Sanoff of the University of North Carolina’s Lineberger Comprehensive Cancer Center, is wary of celebrating but calls the findings compelling. She said, “These results are cause for great optimism, but such an approach cannot yet supplant our current curative treatment approach. The endpoint presented — clinical complete response — is an imperfect surrogate for long-term cancer control,”
It remains to be seen whether the cancer will remerge. The authors noted that a longer follow-up is needed to assess the duration of response.


Down to Earth is Science and Environment fortnightly published by the Society for Environmental Communication, New Delhi. We publish news and analysis on issues that deal with sustainable development, which we scan through the eyes of science and environment.